Their controlled action can control food cravings and reduce hunger as well as calorie intake, thereby reducing weight
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Frohm Nilsson M, Sandstedt B, Srensen O, Weber G, Borregaard N, Sthle-Bckdahl M: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6
Hims plans to wait and see
CBF: cerebral blood flow
Bailey et al.) Metabolic endpoints : Glucose control, appetite regulation, energy expenditure (Statham et al
